Transcript

Matthew Regulski, DPM, FFPM, RCPS (Glasgow):

Hello, my name is Dr. Matthew Regulski. I'm the Medical Director of the Wound Institute of Ocean County in Toms River, New Jersey, Senior Partner at Ocean County Foot and Ankle Surgical Associates in Toms River, New Jersey. I've been in practice 22 years concentrating on diabetic wound healing, limb salvage, and reconstructive surgery. 

In this poster, we are utilizing a product produced by a company called Britecyte. Its name is Liposana. So it's a cryopreserved human fat injection allograft that we are utilizing in the healing of small wounds but also in the spectrum of preventing diabetic foot ulcers. As you're aware, diabetic foot ulcer has a 50% recurrence in a year, 65% recurrence in 3 years, and almost a 95% recurrence in 10 years. A callus in a diabetic neuropathic patient can raise their risk for ulceration 11 times greater. And considering that diabetic foot ulcers carry a 40% to 50% mortality rate, it is imperative that we do things to heal them quickly, scientifically, and with evidence-based practices, but at the same time, preventing the recurrence of the ulceration, because as we heal the wound, we still don't take away all of the complex problems that created the wound. So thus, the higher recurrence rate. 

So by injecting the Liposana allograft product, we were able to use the MIMOSA as well to show over time the increase in vascularity, because fat is highly metabolically active. It has a tremendous angiogenic signaling capability, because it needs a lot of blood flow to meet its high metabolic demand. So thus, utilizing those 2 constructs, we were able to not only heal wounds, but to prove that we improve the vasculature into the wound, which is critical in the formation of granulation tissue and re-epithelialization.